|
Axicabtagene Ciloleucel Clinical Trials
10 actively recruiting trials across 6 locations
Also known as: (Axi-cel-2), Axi-cel, Axicabtagene Ciloleucel Injection, Axicel, KTE C19 +5 more
Pipeline
Phase 1: 2Phase 2: 6Phase 3: 1Phase 4: 1
Top Sponsors
- Zhengzhou University1
- The First Affiliated Hospital of Xiamen University1
- Stanford University1
- SWOG Cancer Research Network1
- Marcela V. Maus, M.D.,Ph.D.1
Indications
- Cancer10
- Large B-cell Lymphoma3
- Refractory Non-Hodgkin Lymphoma3
- Refractory Diffuse Large B-Cell Lymphoma3
- Recurrent Diffuse Large B-Cell Lymphoma3
Other3 trials
Duarte, California2 trials
Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells
City of Hope Medical Center
Phase 2
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
City of Hope Comprehensive Cancer Center
Phase 1
Gilbert, Arizona1 trial
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Banner MD Anderson Cancer Center
Phase 3
Tucson, Arizona1 trial
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Banner University Medical Center - Tucson
Phase 2
Palo Alto, California1 trial
Boston, Massachusetts1 trial
Emapalumab Prevention of CAR-T Cell Associated Toxicities
Massachusetts General Hospital
Phase 2
Houston, Texas1 trial
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.